<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00098969</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000396464</org_study_id>
    <secondary_id>P30CA046592</secondary_id>
    <secondary_id>CCUM-2004-0535</secondary_id>
    <secondary_id>CCUM-2062</secondary_id>
    <nct_id>NCT00098969</nct_id>
  </id_info>
  <brief_title>UMCC 2003-064 Resveratrol in Preventing Cancer in Healthy Participants</brief_title>
  <acronym>IRB 2004-535</acronym>
  <official_title>Phase I Single-Dose Safety and Phamacokinetics Clinical Study of Resveratrol AKA IRB 2003-424</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Chemoprevention is the use of certain drugs to keep cancer from forming, growing,&#xD;
      or coming back. The use of resveratrol may prevent cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of resveratrol in&#xD;
      preventing cancer in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the concentration of resveratrol and its metabolites in the plasma, urine, and&#xD;
           feces of healthy participants.&#xD;
&#xD;
        -  Correlate dose with systemic concentration of this drug and its metabolites in these&#xD;
           participants.&#xD;
&#xD;
        -  Determine the safety of this drug in these participants.&#xD;
&#xD;
      OUTLINE: This is an open-label, dose-escalation, multicenter study.&#xD;
&#xD;
      Beginning 5 days before study drug administration, participants are put on a controlled diet&#xD;
      (avoiding all resveratrol-containing food or drink) for washout. Participants receive oral&#xD;
      resveratrol once on day 1.&#xD;
&#xD;
      Cohorts of 10 participants receive escalating doses of resveratrol until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 10 participants experience dose-limiting toxicity. A total of 16 participants are treated&#xD;
      at the MTD.&#xD;
&#xD;
      Participants are followed at 2 and 7 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-40 participants will be accrued for this study within 6&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>resveratrol</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy participants&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 to 80&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm^3&#xD;
&#xD;
          -  Platelet count 120,000-450,000mm^3&#xD;
&#xD;
          -  Hemoglobin 10.5-17.5 g/dL for women OR 11.5-19.0 g/dL for men&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin 0.05-1.2 mg/dL&#xD;
&#xD;
          -  AST and ALT &lt; 1.5 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Urinalysis normal&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile participants must use effective contraception&#xD;
&#xD;
          -  Willing to abstain from ingesting large quantities of resveratrol-containing foods&#xD;
&#xD;
          -  Willing to spend 24 hours in the hospital&#xD;
&#xD;
          -  No cancer diagnosis that is currently under treatment, is clinically detectable, or&#xD;
             that has been treated within the past 5 years except basal cell or squamous cell skin&#xD;
             cancer&#xD;
&#xD;
          -  No concurrent excessive alcohol intake (&gt;21 units per week for men; 14 units per week&#xD;
             for women)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent hormone replace ment therapy allowed&#xD;
&#xD;
          -  Concurrent oral or depot contraceptives allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 2 weeks since prior and no concurrent vitamin supplements of any type&#xD;
&#xD;
          -  More than 6 months since prior and no concurrent participation in any other&#xD;
             experimental study&#xD;
&#xD;
          -  No other concurrent chronic medications, including over-the-counter medications,&#xD;
             herbal/natural preparations, or dietary supplements&#xD;
&#xD;
          -  No other concurrent prescribed medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dean E. Brenner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Michigan Rogel Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Michigan Comprehensive Cancer Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109-0942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leicester Royal Infirmary</name>
      <address>
        <city>Leicester</city>
        <state>England</state>
        <zip>LE2 7LX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Boocock DJ, Gescher AJ, Brown V, et al.: Phase I single-dose safety and pharmacokinetics clinical study of the potential cancer chemopreventive agent resveratrol. [Abstract] American Association for Cancer Research: 97th Annual Meeting, April 1-5, 2006, Washington, DC. 2006.</citation>
  </results_reference>
  <verification_date>March 2010</verification_date>
  <study_first_submitted>December 8, 2004</study_first_submitted>
  <study_first_submitted_qc>December 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2004</study_first_posted>
  <last_update_submitted>December 13, 2012</last_update_submitted>
  <last_update_submitted_qc>December 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2012</last_update_posted>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Resveratrol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

